Physician profile
Joel See
NPI 1558319897
$2,920.57
in general payments reported to CMS, 2019-2025
20 companies · $406 in 2025
The $406 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $264 · 2021: $312 · 2022: $354 · 2023: $536 · 2024: $791 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,732.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $644.22 | 2019-2025 | Proclaim, Eterna |
| Saluda Medical Americas, INC. | $348.45 | 2024-2025 | Evoke |
| Boston Scientific Corporation | $264.94 | 2020-2021 | |
| Stimwave Technologies Incorporated | $254.91 | 2022 | |
| Mml US, INC. | $169.28 | 2024 | Reactiv8 |
| Nevro Corp. | $169.04 | 2019-2022 | |
| Spr Therapeutics, INC | $153.47 | 2023 | Sprint Pns System |
| Amgen INC. | $143.70 | 2019-2024 | Evenity |
| Nalu Medical, INC. | $143.54 | 2022-2023 | Nalu Neurostimulation System |
| Abbvie INC. | $117.47 | 2022-2025 | Botox |
| Averitas Pharma INC. | $113.19 | 2024 | Qutenza |
| Allergan, INC. | $104.66 | 2020-2021 | |
| Biodelivery Sciences International, INC. | $73.14 | 2019-2020 | |
| Pfizer INC. | $62.70 | 2019-2023 | |
| Collegium Pharmaceutical, INC. | $34.06 | 2023 | Belbuca |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $31.60 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $30.27 | 2025 | |
| Baudax Bio INC. | $21.29 | 2021 | |
| Relievant Medsystems, INC. | $20.37 | 2023 | Intracept |
| Tersera Therapeutics LLC | $20.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel See listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.